According to these findings, when exposed to a higher dose of cisplatin (10 μg/ml), bladder cancer cell lines with high TACC3 or E2F1 expression were both characterized by a strong transactivation response by Bik (Fig. 5e) and Bim (Fig. 5f), which paralleled a severe downregulation of the Bcl-2 gene (Fig. 5g). The gene discussed is BCL2; the disease is urinary bladder carcinoma.